In Response:
Our original intent was to test the hypothesis that L-arginine supplementation would reduce atherosclerosis in apolipoprotein E (apoE) knockout mice by providing substrate for eNOS. 1 In light of recent data that the iNOS isoform is potentially proatherogenic, 2,3 we were concerned that L-arginine might also increase iNOS-derived NO, confounding our results. Thus, we studied both apoE knockout mice and apoE/iNOS double-knockout mice, reasoning that L-arginine could not serve as substrate for iNOS in the double knockout mice. We were surprised to find that L-arginine supplementation did not reduce atherosclerotic burden in the apoE knockout mice, a result in agreement with other reports of the apoE knockout mouse model of atherogenesis. 4 Furthermore, we found that L-arginine supplementation eliminated the protective effect of iNOS deficiency in the apoE/iNOS double-knockout mice. To examine potential mechanisms for these effects, we measured oxidized and reduced biopterin levels, as well as MDA-TBA reactive material as markers of lipid oxidation.
In his accompanying editorial, 5 Loscalzo pointed out another potential mechanism: that L-arginine may increase plasma levels of homocysteine, because creatine synthesis accounts for the major fraction of total body arginine utilization and results in a significant methylation demand. Loscalzo's analysis of the literature and our unexpected results was, we believe, extremely logical and cogent. The hypothesis is an intriguing one. If true, the implications would be very broad indeed, as indiscriminate supplementation with L-arginine may be not be helpful and may in fact be contraindicated. Thus, the hypothesis certainly merits experimental testing.
We have three comments regarding Cooke's and Sydow's letter. First, they do not acknowledge that, while some studies suggest a beneficial effect of L-arginine on atherosclerosis and endothelial function, other studies fail to show such effects. 4, [6] [7] [8] [9] [10] 11 to provide evidence that L-arginine supplementation increases homocysteine levels. Rather, if one reads the editorial carefully, Loscalzo cites numerous references [12] [13] [14] that show that creatine synthesis represents the major fraction of total body arginine utilization, while NO synthesis represents a much lower fraction (1.2%) of arginine flux. Loscalzo cites the article by Stead et al 11 to explain why creatine supplementation would be expected to suppress AGAT expression, thereby decreasing methylation stress. Creatine supplementation would therefore be one means to experimentally test the effects of L-arginine supplementation in vivo.
Third, we agree that hyperhomocysteinemia impairs endothelial function. However, these effects do not negate the possibility that L-arginine supplementation may, under certain conditions, increase homocysteine levels.
We believe the results of our study and the issues raised by Loscalzo in his editorial are best resolved by experimental study, so that we can determine when and if L-arginine supplementation is beneficial and, equally importantly, when it might not be.
Jiqiu Chen Paul Huang
Cardiovascular Research Center, Charlestown, Mass
Should Soluble CD40 Ligand Be Measured From Serum or Plasma Samples?
To the Editor:
We were surprised to read the article by Blake et al 1 on the relationship of soluble CD40 ligand (sCD40L) and lipid accumulation in carotid atheroma. We recently reported an association between inflammatory markers and early onset carotid atherosclerosis. 2 Of the patients noted in that report, we had plasma samples from EDTA-anticoagulated blood, stored frozen for 1 to 3 years. Although the product information and manual of the Bender MedSystem's ELISA kit clearly states that plasma preparations are not suitable for the essay, 3 we decided to run a test on some of these plasma samples for sCD40L. We also used duplicate plasma samples, together with fresh serum and plasma of 5 healthy subjects obtained less than 4 hours before the ELISA test, in the same ELISA plate. We were not surprised but were disappointed, as no activity could be detected either in the frozen plasma samples of patients or in the fresh or recalcified plasma samples of the healthy subjects. The method and the plate worked properly, as sCD40L activity was measured with small variation between duplicates in all of the serum samples (7.0Ϯ1.5 ng/mL, meanϮSD). We had to conclude and admit that, as stated in the product information, EDTA-anticoagulated plasma samples-either frozen or freshly collected-are not appropriate for the test.
After this failure, we came across the article of Blake et al, 1 in which the authors referred to their previous report for the method of sCD40L determination. 4 They used plasma samples from EDTAanticoagulated blood, and the same Bender MedSystem's ELISA kit for the measurements 4 as we did. We checked the methods and found that they used 5-times diluted plasma samples, so we assumed that either the EDTA concentration or something else in our undiluted plasma samples might have caused our failure. Therefore, in a second attempt in 5 subjects, we measured sCD40L activities in parallel serum, plasma, and 5-times diluted plasma. In these 5 subjects, sCD40L activity could be measured in all samples from the serum (2.95Ϯ1.17 ng/mL), but no activity was found in the majority of plasma samples. Just to obtain values, we calculated mean and standard deviation, which were 0.36Ϯ0.51 ng/mL for undiluted plasma samples and 2.88Ϯ2.01 ng/mL for the 5-times diluted plasma samples.
Looking only at the group means, the results might seem as there is no difference between measurements from serum and diluted plasma. However, if we look at the individual data (Figure) it can be seen that although there is good agreement between the duplicates of serum samples (an average 5.9% difference from the mean), the variation is large between the diluted plasma samples of the same individuals, and in 3 of the 5 samples, zero activity was measured in one or both of the duplicates.
In agreement with recent reports 5, 6 and the product information of the ELISA kit, 3 our results also show that measuring sCD40L from EDTA-treated plasma samples is unreliable. Therefore, we also suggest measuring sCD40L activities from serum and not from plasma samples.
Dániel Bereczki Emõke Nagy András Pál Mária T. Magyar József Balla Departments of Neurology (D.B., M.T.M.) and Internal Medicine (E.N., J.B.), University of Debrecen, Health Science and Medical
Center, Debrecen, and Sanofi-Synthelabo Co, Ltd (A.P.), Budapest, Hungary
In Response:
We share the concern of Dr Bereczki and colleagues regarding the importance of using appropriate specimens in the currently available sCD40L ELISAs (Bender MedSystem and R&D) and have referred to this important issue in a recent publication (Schonbeck et al 1 ) .
Several issues are pertinent to the concerns of Dr Bereczki et al:
1. First and foremost, it is of utmost importance to avoid activation of platelets during the post-harvesting sample procedure, because sCD40L can be released within minutes in high concentrations from this cell type. Indeed, platelets are commonly considered the predominant source of sCD40L in the bloodstream. Thus, the sCD40L concentrations obtained in serum, as generated by clotting of whole blood, should be interpreted with care. Indeed, in a previous report, Garlichs et al 2 used serum to measure sCD40L levels and reported an average of 25 ng/mL sCD40L, even in healthy individuals (typically thought to have sCD40 levels Ͻ2 ng/mL). Such concentrations might be considered the "absolute blood level of sCD40L," combining freely circulating sCD40L and CD40L expressed in circulating cells, namely platelets, T cells, and mononuclear phagocytes. Therefore, the authors (and other groups with whom the authors have communicated in recent years) consider the use of serum specimens to determine circulating sCD40L levels to be questionable. 2. In light of the above, it is commonly considered crucial to remove platelets from blood preparations without activation if one desires to determine the levels of freely circulating sCD40L. Indeed, the authors have performed extensive studies comparing levels of sCD40L in serum, platelet-rich plasma, platelet-poor plasma and plasma centrifuged at 2000g (the technique the authors used). Platelet counts and sCD40L levels detected in these healthy subjects are shown in the Table, demonstrating that, in our hands, removal of platelets is crucial for appropriate analysis. 3. The authors have informed Bender MedSystems about these circumstances, suggesting respective modifications in their protocol. 4. Using plasma, the authors have furthermore compared Heparin, Citrate, and EDTA as anticoagulants. Although Citrate provided the highest reproducibility, EDTA also yielded reliable and reproducible read-outs (variation coefficientϽ10%). These data were verified in "spiking experiments," in which recombinant sCD40L was added to plasma samples of healthy or atherosclerotic subjects and recovery rates determined. fashion similar to that used by the authors) indeed provide comparable data (with cases 1, 3, and 5, demonstrating rather marginal standard variations). Also, it remains to be determined why the high standard deviations were observed in only 2 of 5 samples; if EDTA comprises a more generic problem for the ELISA, values would be expected "all over the place." Unfortunately however, Bereczki et al do not provide any information regarding the platelet contamination in their preparations, information that might be crucial to understand their findings better.
